AZN实时信号 | 通过Getagraph.com最大化利润

出售 3918 min ago

@ $75.11

发出时间: 26 Apr 2024 @ 23:27

回报率: 0.08%

上一信号: Apr 26 - 21:32

上一信号: 购买

回报率: 0.30 %

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

Stats
今日成交量	6.19M
平均成交量	6.39M
市值	233.01B
EPS	$0 ( 2024-04-25 )
Last Dividend	$0.985 ( 2024-02-22 )
Next Dividend	$0 ( N/A )
P/E	39.77
ATR14	$0.900 (1.20%)

音量相关性

長: -0.84 (strong negative)

短: 0.82 (strong)

Signal:(49) Same movement expected

Astrazeneca PLC 相关性

10 最正相关
COM	0.892
JE	0.887
CS	0.887
DPG	0.876
RYF	0.865
CWT	0.859
XPOF	0.855
FRC-PI	0.853
VNCE	0.852
FRC-PH	0.851

10 最负相关
DCT	-0.866
CODI-PC	-0.864
LAD	-0.86
DBMF	-0.853
TDG	-0.844
NR	-0.843
AEL	-0.842
OSH	-0.839
MSA	-0.835
CINR	-0.831

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Astrazeneca PLC 相关性 - 货币/商品

0.15
( neutral )

-0.61
( weak negative )

0.00
( neutral )

-0.21
( neutral )

-0.03
( neutral )

-0.17
( neutral )

Astrazeneca PLC 财务报表

Annual	2023
营收:	$45.81B
毛利润:	$37.54B (81.95 %)
EPS:	$1.920

FY	2023
营收:	$45.81B
毛利润:	$37.54B (81.95 %)
EPS:	$1.920

FY	2022
营收:	$44.35B
毛利润:	$31.96B (72.06 %)
EPS:	$1.060

FY	2021
营收:	$37.42B
毛利润:	$24.98B (66.76 %)
EPS:	$0.0400

Financial Reports:

No articles found.

Astrazeneca PLC Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.465 (N/A)	$0 (N/A)	$0.985 (N/A)	$0 (N/A)	$0.465 (N/A)	$0 (N/A)	$0.985 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Astrazeneca PLC Dividend Information - Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 6.44 - Stable (28.89%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.0965	1993-09-24
Last Dividend	$0.985	2024-02-22
Next Dividend	$0	N/A
Payout Date	2024-03-25
Next Payout Date	N/A
# dividends	63	--
Total Paid Out	$29.01	--
Avg. Dividend % Per Year	2.09%	--
Score	4.96	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	6.44
Div. Directional Score	8.30	--

Next Divdend (Est)
(2024-06-28)

$1.009 Estimate 18.78 %

Dividend Stability

0.50 Average

Dividend Score

4.96

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield
1993	$0.0965	1.91%
1994	$0.260	4.21%
1995	$0.287	4.20%
1996	$0.247	2.50%
1997	$0.357	2.61%
1998	$0.398	2.19%
1999	$0.303	1.33%
2000	$0.926	4.50%
2001	$0.389	1.53%
2002	$0.389	1.70%
2003	$0.389	2.23%
2004	$0.418	1.71%
2005	$0.513	2.83%
2006	$0.705	2.80%
2007	$0.875	3.25%
2008	$0.950	4.48%
2009	$1.045	5.15%
2010	$1.205	5.08%
2011	$1.350	5.82%
2012	$1.425	5.97%
2013	$1.400	5.80%
2014	$1.400	4.78%
2015	$1.400	3.98%
2016	$1.400	4.19%
2017	$1.400	5.05%
2018	$1.400	3.96%
2019	$1.400	3.70%
2020	$1.400	2.78%
2021	$1.400	2.77%
2022	$1.450	2.49%
2023	$1.450	2.09%
2024	$0.985	1.44%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for NYSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
LOMA	Dividend Knight	2023-06-30	Quarterly	2	5.23%	8.53
KIO	Dividend Royal	2023-12-14	Monthly	12	7.05%	8.50
NCZ	Dividend Royal	2024-02-09	Monthly	22	7.79%	8.50
SCM	Dividend King	2023-12-15	Monthly	13	7.08%	8.50
SJT	Dividend Royal	2023-11-29	Monthly	39	12.52%	8.50
GOF	Dividend Royal	2023-11-14	Monthly	18	8.03%	8.50
SRV	Dividend Royal	2023-12-04	Monthly	18	7.53%	8.50
VGI	Dividend Royal	2024-02-09	Monthly	13	7.36%	8.50
JQC	Dividend Royal	2023-11-14	Monthly	22	6.56%	8.50
PHK	Dividend Royal	2023-11-10	Monthly	22	6.88%	8.50

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.130	1.500	7.40	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0589	1.200	8.04	9.64	[0 - 0.3]
returnOnEquityTTM	0.159	1.500	9.34	10.00	[0.1 - 1]
payoutRatioTTM	0.752	-1.000	2.48	-2.48	[0 - 1]
currentRatioTTM	0.820	0.800	-0.898	-0.719	[1 - 3]
quickRatioTTM	0.636	0.800	-0.967	-0.774	[0.8 - 2.5]
cashRatioTTM	0.191	1.500	-0.0488	-0.0732	[0.2 - 2]
debtRatioTTM	0.283	-1.500	5.28	-7.92	[0 - 0.6]
interestCoverageTTM	5.13	1.000	9.21	9.21	[3 - 30]
operatingCashFlowPerShareTTM	3.31	2.00	8.90	10.00	[0 - 30]
freeCashFlowPerShareTTM	2.10	2.00	8.95	10.00	[0 - 20]
debtEquityRatioTTM	0.731	-1.500	7.08	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.820	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	0.179	1.000	8.42	8.42	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.361	1.000	9.10	9.10	[0.2 - 2]
assetTurnoverTTM	0.453	0.800	-0.313	-0.250	[0.5 - 2]
Total Score				10.16

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	39.41	1.000	6.12	0	[1 - 100]
returnOnEquityTTM	0.159	2.50	9.58	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	2.10	2.00	9.30	10.00	[0 - 30]
dividendYielPercentageTTM	1.929	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	3.31	2.00	8.90	10.00	[0 - 30]
payoutRatioTTM	0.752	1.500	2.48	-2.48	[0 - 1]
pegRatioTTM	1.224	1.500	5.17	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.226	1.000	6.85	0	[0.1 - 0.5]
Total Score				6.44

Astrazeneca PLC

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.